Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has partnered with Clinilabs Drug Development Corporation to work on its upcoming phase 1/2a clinical trial of CYB003. Clinilabs is a global, full-service contract research organization that has built a reputation for its expertise in central nervous system drug development. Derived from psilocybin, Cybin’s CYB003 is part of a family of molecules called indolamines that include common neurotransmitters such as serotonin. The molecule will be the first psilocybin analog to be evaluated in phase 1/2a development for the treatment of major depressive disorder (“MDD”). According to Clinilabs management, an estimated one-third to one-half of people struggling with MDD don’t respond to current antidepressant drug treatment, with the only options for treatment being escalating dosage amounts or changing medication. Clinilabs management called working with Cybin to conduct the first-in-human clinical trial of CYB003 a “privilege.” Cybin management is also looking forward to the collaboration. “We are delighted to partner with the Clinilabs team as we progress this important program toward a first-in-human Phase 1/2a trial,” said Cybin CEO Doug Drysdale in the press release. “Clinilabs brings a unique combination of scientific and operational experience and deep expertise in clinical research across a range of psychiatric, neurological and substance use disorders. Clinilabs is ideally suited to help us accelerate the regulatory pathway for this promising treatment candidate and ultimately, to effectively treat those suffering with MDD.”
To view the full press release, visit https://ibn.fm/d07hd
About Cybin Inc.
Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork